Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Glaukos is a leader in the ophthalmic pharmaceutical and medical technology market, offering a unique solution for the treatment of glaucoma, corneal disorders, and retinal diseases with its dropless therapy iDose TR. Despite potential uncertainty surrounding proposed changes in reimbursement policy, Glaukos is well-positioned for continued revenue growth from a diverse portfolio of products, including iStent and iDose TR, and the potential for Epioxa to significantly contribute to revenue in the future. With a solid pipeline, strong execution potential, and a competitive market position, Glaukos's stock presents an attractive investment opportunity.

Bears say

Glaukos is facing some potential headwinds in its iDose sales due to the proposed LCD, which may result in a -25% impact to iDose volumes on a weighted average basis for CY25 volumes. Additionally, there is potential for a -10% or -$30M of iDose revenue in CY27. Despite this, there are potential offsets for iDose from other sources such as Medicare Advantage patients and the Epioxa launch, but the impact on iDose is still a concern. There is also some potential downside risk in the bear case scenario, but overall, the outlook for Glaukos is still strong with a focus on innovative therapies for glaucoma, corneal disorders, and retinal diseases.

Glaukos (GKOS) has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Strong Buy based on their latest research and market trends.

According to 12 analysts, Glaukos (GKOS) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $149.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $149.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.